Clinical potential of the mTOR targets S 6 K 1 and S 6 K 2 in breast cancer
暂无分享,去创建一个
L. Skoog | O. Stål | B. Nordenskjöld | T. Fornander | E. Karlsson | B. Olsson | G. Pérez-Tenorio | Marie Ahnström | B. Holmlund | Birgitta Holmlund
[1] L. Skoog,et al. Mutation and accumulation of p53 related to results of adjuvant therapy of postmenopausal breast cancer patients , 2004, Acta oncologica.
[2] J. Ptak,et al. High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.
[3] M. J. van de Vijver,et al. Overexpression of P70 S6 kinase protein is associated with increased risk of locoregional recurrence in node-negative premenopausal early breast cancer patients , 2004, British Journal of Cancer.
[4] W. Sauerbrei,et al. REporting recommendations for tumor MARKer prognostic studies (REMARK) , 2005, Nature Clinical Practice Oncology.
[5] T. Ohnishi,et al. In vitro and in vivo potentiation of radiosensitivity of malignant gliomas by antisense inhibition of the RAD51 gene. , 1998, Biochemical and biophysical research communications.
[6] Olle Stål,et al. Akt kinases in breast cancer and the results of adjuvant therapy , 2003, Breast Cancer Research.
[7] L. Skoog,et al. c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer. , 1995, European journal of cancer.
[8] Stefano Fumagalli,et al. Disruption of the p70s6k/p85s6k gene reveals a small mouse phenotype and a new functional S6 kinase , 1998, The EMBO journal.
[9] T. Singleton,et al. Clinical and pathologic significance of the c-erbB-2 (HER-2/neu) oncogene. , 1992, Pathology annual.
[10] Hyun-Ah Kim,et al. Activation of the mTOR signaling pathway in breast cancer and its correlation with the clinicopathologic variables , 2008, Breast Cancer Research and Treatment.
[11] M. Holz,et al. S6 Kinase 1 Regulates Estrogen Receptor α in Control of Breast Cancer Cell Proliferation* , 2009, Journal of Biological Chemistry.
[12] K. Camphausen,et al. Gleevec-mediated inhibition of Rad51 expression and enhancement of tumor cell radiosensitivity. , 2003, Cancer research.
[13] Simak Ali,et al. Phosphorylation of Estrogen Receptor-α at Ser167 Is Indicative of Longer Disease-Free and Overall Survival in Breast Cancer Patients , 2007, Clinical Cancer Research.
[14] J. Blenis,et al. Characterization of S6K2, a novel kinase homologous to S6K1 , 1999, Oncogene.
[15] D. Albertson,et al. Gene amplification in cancer. , 2006, Trends in genetics : TIG.
[16] H. Yamashita,et al. Phosphorylation of estrogen receptor α serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer , 2005, Breast Cancer Research.
[17] W. Gullick,et al. c-erbB2 amplification and overexpression in human tumors. , 1992, Cancer treatment and research.
[18] In-Hyun Park,et al. Regulation of Ribosomal S6 Kinase 2 by Mammalian Target of Rapamycin* , 2002, The Journal of Biological Chemistry.
[19] Wolfgang Eiermann,et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] L. Skoog,et al. PIK3CA Mutations and PTEN Loss Correlate with Similar Prognostic Factors and Are Not Mutually Exclusive in Breast Cancer , 2007, Clinical Cancer Research.
[21] L. Skoog,et al. Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer , 2007, Oncogene.
[22] R. Pearson,et al. Coordinate regulation of ribosome biogenesis and function by the ribosomal protein S6 kinase, a key mediator of mTOR function , 2007, Growth factors.
[23] R. Greil,et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] H. Johansson,et al. Long-term follow-up of the Stockholm randomized trials of postoperative radiation therapy versus adjuvant chemotherapy among ‘high risk’ pre- and postmenopausal breast cancer patients , 2006, Acta oncologica.
[25] Shiuan Chen,et al. The molecular basis of the interaction between the proline-rich SH3-binding motif of PNRC and estrogen receptor alpha , 2006, Nucleic acids research.
[26] Stefano Fumagalli,et al. S6K1−/−/S6K2−/− Mice Exhibit Perinatal Lethality and Rapamycin-Sensitive 5′-Terminal Oligopyrimidine mRNA Translation and Reveal a Mitogen-Activated Protein Kinase-Dependent S6 Kinase Pathway , 2004, Molecular and Cellular Biology.
[27] Andrew R. Green,et al. CCND1 amplification and cyclin D1 expression in breast cancer and their relation with proteomic subgroups and patient outcome , 2008, Breast Cancer Research and Treatment.
[28] R. Schiff,et al. Unraveling the Mechanisms of Endocrine Resistance in Breast Cancer: New Therapeutic Opportunities , 2007, Clinical Cancer Research.
[29] T. Ohnishi,et al. Antisense inhibition of the RAD51 enhances radiosensitivity. , 1996, Biochemical and biophysical research communications.
[30] I. Bièche,et al. Novel approach to quantitative polymerase chain reaction using real‐time detection: Application to the detection of gene amplification in breast cancer , 1998, International journal of cancer.
[31] Fergus J. Couch,et al. The 17q23 Amplicon and Breast Cancer , 2003, Breast Cancer Research and Treatment.
[32] O. Stål,et al. Activation of the phosphatidylinositol 3-kinase/Akt pathway prevents radiation-induced apoptosis in breast cancer cells. , 2005, International journal of oncology.
[33] H. Johansson,et al. Long-term follow-up of the randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancer , 2007, Acta oncologica.
[34] Manuel Hidalgo,et al. Inhibition of mTOR Activity Restores Tamoxifen Response in Breast Cancer Cells with Aberrant Akt Activity , 2004, Clinical Cancer Research.
[35] E. Hafen,et al. Drosophila S6 kinase: a regulator of cell size. , 1999, Science.
[36] F. Couch,et al. Localization of PS6K to chromosomal region 17q23 and determination of its amplification in breast cancer. , 1999, Cancer research.
[37] K. Ang,et al. Sensitization of breast cancer cells to radiation by trastuzumab. , 2003, Molecular cancer therapeutics.
[38] D. Kupferwasser,et al. Mutational analysis of ribosomal S6 kinase 2 shows differential regulation of its kinase activity from that of ribosomal S6 kinase 1. , 2003, The Biochemical journal.
[39] L. Skoog,et al. Ratio of 17HSD1 to 17HSD2 Protein Expression Predicts the Outcome of Tamoxifen Treatment in Postmenopausal Breast Cancer Patients , 2009, Clinical Cancer Research.
[40] J. Blenis,et al. Molecular mechanisms of mTOR-mediated translational control , 2009, Nature Reviews Molecular Cell Biology.
[41] Hanina Hibshoosh,et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. , 2005, Cancer research.
[42] Jiang Shou,et al. Cross-Talk between Estrogen Receptor and Growth Factor Pathways as a Molecular Target for Overcoming Endocrine Resistance , 2004, Clinical Cancer Research.
[43] Shiuan Chen,et al. Dual Inhibition of mTOR and Estrogen Receptor Signaling In vitro Induces Cell Death in Models of Breast Cancer , 2005, Clinical Cancer Research.
[44] L. Skoog,et al. The BRCA1/BRCA2/Rad51 complex is a prognostic and predictive factor in early breast cancer. , 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[45] H. Kurokawa,et al. ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[46] David M Sabatini,et al. Defining the role of mTOR in cancer. , 2007, Cancer cell.
[47] Valeriy Filonenko,et al. Immunohistochemical analysis of Ki-67, PCNA and S6K1/2 expression in human breast cancer. , 2005, Experimental oncology.
[48] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.
[49] Peter Schraml,et al. Prognostic Relevance of Gene Amplifications and Coamplifications in Breast Cancer , 2004, Cancer Research.
[50] K. Jirström,et al. Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification. , 2005, Cancer research.
[51] D. Birnbaum,et al. BMC Cancer , 2003 .